Skip to main content
. 2022 Feb 22;2022:8367997. doi: 10.1155/2022/8367997

Figure 7.

Figure 7

ML385 abolishes the cardioprotective effects of diosmetin in vitro. (a) qPCR analysis of mRNA of hypertrophy-related genes (ANP, BNP, and β-MHC) in NRCMs following stimulation with ML385, n = 3, ∗p <0.05, ∗∗p < 0.01 vs. the PBS group; #p <0.05, ##p < 0.01 vs. the PE group; $p <0.05 vs. PE+Dio. (b) Western blot of HO-1, SOD2, and p62 expressions in NRCMs with GAPDH as the control. (c) Quantitative analysis of (b), ∗p <0.05, ∗∗p < 0.01 vs. the PE group; #p <0.05, ##p < 0.01 vs. PE+Dio. Data are presented as mean ± SEM. ns: not significant. (d) A mechanism model diagram for the anticardiac hypertrophy effect of diosmetin.